Inari Medical Q1 EPS Forecast Lowered by Leerink Partnrs

Inari Medical, Inc. (NASDAQ:NARI - Free Report) - Equities research analysts at Leerink Partnrs dropped their Q1 2025 earnings per share estimates for Inari Medical in a research note issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now forecasts that the company will post earnings of $0.02 per share for the quarter, down from their prior forecast of $0.03. Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Inari Medical's current full-year earnings is ($0.77) per share. Leerink Partnrs also issued estimates for Inari Medical's FY2025 earnings at $0.18 EPS and FY2026 earnings at $0.29 EPS.

A number of other research firms have also recently weighed in on NARI. Truist Financial raised their target price on Inari Medical from $46.00 to $50.00 and gave the company a "hold" rating in a research note on Tuesday, October 29th. Stifel Nicolaus started coverage on shares of Inari Medical in a research report on Tuesday, September 17th. They set a "hold" rating and a $50.00 price target for the company. Wells Fargo & Company dropped their price target on shares of Inari Medical from $84.00 to $65.00 and set an "overweight" rating for the company in a research note on Wednesday, July 31st. Deutsche Bank Aktiengesellschaft began coverage on shares of Inari Medical in a research note on Friday, August 9th. They set a "buy" rating and a $68.00 price objective on the stock. Finally, Leerink Partners initiated coverage on shares of Inari Medical in a research report on Tuesday, September 3rd. They issued a "market perform" rating and a $47.00 target price for the company. Six research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $58.89.

Inari Medical Stock Up 0.4 %

Shares of NARI traded up $0.20 during mid-day trading on Wednesday, reaching $51.03. 532,896 shares of the stock traded hands, compared to its average volume of 983,324. The stock has a fifty day simple moving average of $45.86 and a 200 day simple moving average of $47.43. The firm has a market cap of $2.99 billion, a price-to-earnings ratio of -37.65 and a beta of 0.96. Inari Medical has a 12-month low of $36.73 and a 12-month high of $67.13.

Institutional Investors Weigh In On Inari Medical

A number of hedge funds have recently made changes to their positions in the business. Vestal Point Capital LP grew its holdings in Inari Medical by 342.9% in the 3rd quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company's stock worth $63,922,000 after buying an additional 1,200,000 shares in the last quarter. Point72 Asset Management L.P. grew its stake in shares of Inari Medical by 113.3% in the second quarter. Point72 Asset Management L.P. now owns 1,481,283 shares of the company's stock worth $71,324,000 after purchasing an additional 786,691 shares in the last quarter. Armistice Capital LLC increased its holdings in shares of Inari Medical by 353.1% during the second quarter. Armistice Capital LLC now owns 1,009,252 shares of the company's stock valued at $48,595,000 after purchasing an additional 786,501 shares during the period. Jennison Associates LLC raised its stake in shares of Inari Medical by 63.2% during the third quarter. Jennison Associates LLC now owns 1,576,641 shares of the company's stock valued at $65,021,000 after purchasing an additional 610,468 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Inari Medical by 11.1% in the first quarter. Vanguard Group Inc. now owns 5,599,854 shares of the company's stock worth $268,681,000 after purchasing an additional 561,562 shares during the period. Institutional investors own 90.98% of the company's stock.

Insider Activity at Inari Medical

In other news, CFO Mitch C. Hill sold 3,000 shares of the business's stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $45.13, for a total transaction of $135,390.00. Following the completion of the transaction, the chief financial officer now owns 179,600 shares of the company's stock, valued at approximately $8,105,348. The trade was a 1.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director William Hoffman sold 60,000 shares of the company's stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $51.16, for a total transaction of $3,069,600.00. Following the transaction, the director now owns 501,233 shares of the company's stock, valued at $25,643,080.28. This represents a 10.69 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 186,000 shares of company stock valued at $8,990,990 in the last quarter. Insiders own 10.60% of the company's stock.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.